Strain-induced vascular endothelial cell proliferation requires PI3K-dependent mTOR-4E-BP1 signal pathway

Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1591-7. doi: 10.1152/ajpheart.00382.2004. Epub 2004 Dec 9.

Abstract

The aim of this study was to determine whether the phosphatidylinositol 3-kinase (PI3K)-dependent mammalian target of rapamycin (mTOR)-eukaryotic initiation factor 4E binding protein 1 (4E-BP1) signal pathway and S6 kinase (S6K), the major element of the mTOR pathway, play a role in the enhanced vascular endothelial cell (EC) proliferation induced by cyclic strain. Bovine aortic ECs were subjected to an average of 10% strain at a rate of 60 cycles/min for < or =24 h. Cyclic strain-induced EC proliferation was reduced by pretreatment with rapamycin but not the MEK1 inhibitor PD-98059. The PI3K inhibitors wortmannin and LY-294002 also attenuated strain-induced EC proliferation and strain-induced activation of S6K. Rapamycin but not PD-98059 prevented strain-induced S6K activation, and PD-98059 but not rapamycin prevented strain-induced activation of extracellular signal-regulated kinases 1 and 2. Cyclic strain also activated 4E-BP1, which could be inhibited by PI3K inhibitors. These data suggest that the PI3K-dependent S6K-mTOR-4E-BP1 signal pathway may be critically involved in strain-induced bovine aortic EC proliferation.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3-Phosphoinositide-Dependent Protein Kinases
  • Androstadienes / pharmacology
  • Animals
  • Antibiotics, Antineoplastic / pharmacology
  • Aorta / cytology
  • Carrier Proteins / metabolism*
  • Cattle
  • Cell Division / drug effects
  • Cell Division / physiology
  • Cells, Cultured
  • Chromones / pharmacology
  • Endothelium, Vascular / cytology*
  • Endothelium, Vascular / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Morpholines / pharmacology
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphoproteins / metabolism*
  • Phosphorylation
  • Protein Kinases / metabolism*
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-akt
  • Ribosomal Protein S6 Kinases / metabolism
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases
  • Wortmannin

Substances

  • 3-Phosphoinositide-Dependent Protein Kinases
  • Androstadienes
  • Antibiotics, Antineoplastic
  • Carrier Proteins
  • Chromones
  • Enzyme Inhibitors
  • Flavonoids
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Morpholines
  • Phosphatidylinositol 3-Kinases
  • Phosphodiesterase Inhibitors
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphoproteins
  • Protein Kinases
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-akt
  • Ribosomal Protein S6 Kinases
  • Sirolimus
  • TOR Serine-Threonine Kinases
  • Wortmannin
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one